$56.61
+1.84 (+3.36%)
Open$55.20
Previous Close$54.77
Day High$57.38
Day Low$55.13
52W High$72.36
52W Low$11.40
Volume—
Avg Volume480.2K
Market Cap1.67B
P/E Ratio—
EPS$-0.88
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
-8.5% upside
Current
$56.61
$56.61
Target
$51.79
$51.79
$39.42
$51.79 avg
$66.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 241.80M | 82.73M | 183.45M |
| Net Income | -13,637,400 | -118,469,876 | 2.09M |
| Profit Margin | -5.6% | -151.2% | 1.1% |
| EBITDA | 49.94M | -141,571,926 | 3.06M |
| Free Cash Flow | — | — | 1.04M |
| Rev Growth | +183.6% | +13.1% | +5.3% |
| Debt/Equity | 7.43 | 4.99 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |